High-dose chemotherapy and autologous stem cell transplant (ASCT) is the standard approach for chemosensitive, relapsed aggressive non-Hodgkin's lymphoma (NHL). Various conditioning regimens have been used as treatment before ASCT and disease-free (DFS) and overall survival (OS) rates range from 34 to 60% and 26 to 46%, respectively. To date, few comparative randomized trials have been performed and no regimen has demonstrated superiority to another. Reduction of disease relapse remains the major hurdle for improving patient outcome and in vitro and in vivo purging of lymphoma cells has not necessarily enhanced results. Rituximab pre-mobilization and post-transplant appear to provide better response rates with OS approaching 87-91% at 2-3 years. Newer approaches with radioimmunotherapy may raise DFS to 78% and OS to 93%, albeit with short follow-up. Advances in the conditioning regimens and supportive care have reduced transplant-related mortality to less than 10%. In this review we discuss commonly utilized conditioning regimens, describe their pros and cons and address purging and present conditioning strategies. Owing to the poor outcome with conventional chemotherapy in mantle cell, Burkitt's and T-cell lymphoma, we propose the standard approach of frontline ASCT for these high-risk lymphoma patients. Finally, we will present novel strategies, which can enhance the anti-lymphoma effect, at the same time reducing toxicity, to improve the outcome of ASCT in NHL patients.
Introduction
The Parma group study, a randomized multi-center trial for relapsed aggressive non-Hodgkin's lymphoma (NHL), established the superiority of high-dose chemotherapy and autologous stem cell transplant (ASCT) over conventional salvage chemotherapy. 1 Subsequently, ASCT has become a standard approach for relapsed NHL. Various conditioning regimens have been developed as alternatives to improve upon ASCT results. To date, however, no comparative randomized trials have been performed and the optimal approach remains undetermined. In this review we will discuss commonly utilized conditioning regimens, describe their pros and cons, address NHL purging and present data showing that this field still has a long untraveled road toward 'curing' relapsed aggressive NHL.
Original approach
Initial studies in relapsed aggressive NHL incorporated total body irradiation (TBI) into the conditioning regimen approach as the mainstay of therapy for chemosensitive NHL. Philip et al. 1 used cyclophosphamide and TBI and demonstrated a complete remission rate of 84% and a disease-free survival (DFS) and overall survival (OS) of 46 and 53%, respectively. Re-analysis of these data with 8 years of follow-up has confirmed the excellent response in the transplant arm. 2 This approach was considered reasonable and effective at the time. Tissue dose limitations, however, prohibit the use of TBI in patients who have received prior consolidative or salvage radiation after initial chemotherapy. More importantly, a significant proportion of the patients treated with ASCT subsequently have developed secondary myelodysplasia or acute leukemia, raising concern about the use of TBI in the conditioning regimen. 3 Retrospective analyses of studies using chemotherapy-based conditioning regimens have noted a lower incidence of myelodysplasia and acute leukemia. summarized in Table 1 . This chemotherapy-based approach typically consists of 2-4 drug combinations, including alkylating agents given over 6-7 consecutive days. Patients tolerate these regimens quite well and engraftment is prompt and similar among these combinations. These combination treatments induce complete remissions in the 60-85% range while at 2-5 years after ASCT have resulted in 34-60% DFS and 26-46% OS rates. These drug regimens differ in the potential toxicity with a treatment-related mortality ranging from 3.8 to 17%. Table 2 describes the drugs commonly used in chemotherapy conditioning and their immediate and delayed side effects. Busulfan-containing regimens [6] [7] [8] [9] are frequently associated with hepatic veno-occlusive disease/ sinusoidal obstruction syndrome, especially when combined with thiotepa. Pulmonary toxicity (interstitial pneumonia) has also been described. Carmustine (BCNU)-containing regimens such as BEAM 5 and CBV 10, 11 are also associated with a higher incidence of pulmonary toxicity (pulmonary fibrosis) due to metabolites of the drug. Etoposide-containing regimens 5,10-13 have higher rates of mucositis and the late development of myelodysplasia and acute leukemia. Cytarabine in high doses can produce cerebellar toxicity.
Variability among the studies and lack of information make direct comparison of the results obtained exceedingly difficult. Table 3 describes the limitation of assessing data from the various autologous transplant conditioning studies. The patient characteristics have varied from study to study, and most have not used the International Prognostic Index 14 for aggressive NHL to classify their patients. In addition, many of these studies combined Hodgkin's lymphoma patients with the NHL patients. Furthermore, the remission status (first or second remission, chemosensitive disease versus refractory/ resistant patients) at time of transplant, vary from study to study. Information on molecular and cytogenetic risk factors is also lacking. Finally, studies have included patients who may and may not have received immunotherapy as a purging method before transplant. In general, a transplant center's choice of regimen largely is based on experience with the regimens through local or national clinical trials. Comfort with the regimen and recognition of expected treatment-related toxicity also plays a role.
Despite all the experience and information gathered on this disease there remains no regimen that has demonstrated superiority. Studies recently published appear to show less toxicity, but no significant improvements in DFS or OS rates. Improving upon currently available conditioning regimens remains a major goal. The Dana-Farber group demonstrated that in vitro purging of the marrow product to the point of PCR negativity improved outcome of low-grade lymphoma patients undergoing autologous transplant. 16 Whether this approach demonstrated an effect of the purging or reflects the disease burden or chemosensitivity, that is 'purgability' is still under debate. Other investigators have suggested the ability to purge aggressive lymphoma from the bone marrow product is much more difficult. 17 Patients who have evidence of bone marrow or peripheral blood stem cell tumor contaminated grafts, however, have a worse DFS and OS when compared to those given products in which tumor cannot be detected. 17, 18 Purging strategies in vitro have included anti-lymphoma ('negative selection') approaches including use of monoclonal antibodies with compliment, and immunotoxins (B4-blocked ricin). Another approach has been to select out CD34 þ cells using techniques such as an immunomagnetic bead system, that is 'positive selection'. 19 The ex vivo purge is efficient in removing B-cells from the product and allows for a viable graft, albeit at a significant loss of CD34 þ cells from the original product. This maneuver often results in a delay in the neutrophil and platelet recovery. Randomized prospective studies, however, have not proven these approaches to improve OS, probably because the conditioning regimen cannot eradicate residual disease within the host. 19, 20 Rituximab No randomized trials have demonstrated a clear advantage of in vitro purging strategies. 21 Rituximab, an anti-CD20 chimeric antibody that works via complement-mediated cytotoxicity as well as by antibody-dependent cell-mediated cytotoxicity, effectively eliminates circulating B cells for an extended period of time after its administration. In today's climate of medical practice, the use of rituximab as an adjunct to initial or salvage chemotherapy 22, 23 makes it extremely difficult to find a patient who is immunotherapy naı¨ve entering into transplant. Studies using rituximab in the peri-transplant period are summarized in Table 4 . Flohr et al. 33 conducted a study to evaluate the safety and effectiveness of rituximab in combination with DexaBEAM as mobilization therapy in 27 B-cell lymphoma patients. They showed significant depletion of peripheral B cells without engraftment delays. OS and progression-free survival (PFS) at 16 months after ASCT were 95 and 77%, respectively.
Flinn et al. 24 used a similar approach by adding rituximab to high-dose cyclophosphamide as the mobilization regimen in 25 B-cell lymphoma patients. In addition, the investigators treated patients post-transplant with one dose of rituximab, 7 days after platelet transfusion independence was achieved. Using PCR technology, six of seven evaluable stem cell products were rendered free of tumor contamination. A recent follow-up of the expanded study reported that the projected 3-year OS and relapsefree survival to be 91 and 84%, respectively. Khouri et al. 25 and the MD Anderson Cancer Center used premobilization rituximab followed by BEAM in combination with highdose rituximab (1000 mg/m 2 ) after transplant. Sixty-seven aggressive NHL patients treated with this approach successfully underwent stem cell harvest and transplantation. Although follow-up is short at 20 months, 2 year DFS and OS were 67 and 87%, respectively, significantly better than historic controls. Despite the lack of randomized, prospective trials, these favorable data apparently have persuaded many investigators and transplant centers to incorporate rituximab therapy into the peri-transplant period.
One drawback to the use of rituximab in the peritransplant period includes an increase in opportunistic infections such as CMV disease. 33 This finding may reflect B-cell depletion and resulting hypogammaglobulinemia in these patients. Transient pancytopenia, another cause for the increase in infections, occurred in 6 of 23 patients treated with rituximab after transplant. 24 Some reports have demonstrated impairment of mobilization and harvesting of stem cells and sequent delayed recovery of the platelets after transplant.
22,25
The use of radiolabeled antibodies offers potential advantages over the unconjugated monoclonal antibodies in the setting of high-dose cytotherapy and ASTC. The addition of the radioactive component of the radioimmunoconjugate offers the potential to treat both CD20-positive tumor cells as well as CD20 negative cells through a 'cross-fire' effect. Table 4 describes the current experience with radiolabeled immunotherapy as a component of ASCT.
Press et al. 26 were among the first to investigate this novel approach in a landmark phase-I study in which 24 patients received two different 131 I-labeled anti-CD-20 antibody ( 131 I-tositumomab) doses, followed by ASCT. Owing to cardiopulmonary complications in two patients, the total calculated radiation dose to the lungs was limited not to exceed 2750 cGy. Median OS was 21 þ months after ASCT in this trial. This group reported a follow-up phase-II study showing 2-year PFS and OS rates of 62 and 93%, respectively, results that compare favorably to historic controls generated by the Fred Hutchinson Cancer Research Center. 27 This group logically took these data forward in an effort to eliminate TBI and provide the additional anti-lymphoma therapy in the form of a radioimmunoconjugate combined with high-dose etoposide, cyclophosphamide and ASCT in a phase I/II trial. 28 Mucositis (predominantly grades 1-2) occurred in 92% of patients. Nausea, infection, or the combination occurred in 62% of subjects while transiently elevated liver function abnormalities developed in 42 (81%) patients. Eight of 52 patients treated experienced grade 3-4 toxic effects that included fatal infection (n ¼ 4), pulmonary (ARDS) injury (n ¼ 3), gastrointestinal dysfunction (n ¼ 2) and one each hepatic, renal and mucosal injury. One patient developed grade 3 hepatic veno-occlusive disease/ sinusoidal obstruction syndrome. They reported the maximal tolerated dose of 131 I-tositumomab to be 2500 cGy to critical normal organs (lung, liver and kidneys). Late effects included blood TSH elevations in 56% of the 46 patients tested. Interstitial pneumonitis also occurred in four patients at 2-8 months after dosing of 131 I-tositumomab. Two-year OS and DFS after ASCT were 83 and 68%, respectively, results again comparable to 'controls' treated at their center using TBI, etoposide and cyclophosphamide.
More recently, Vose et al. 29 at the University of Nebraska developed a regimen incorporating 131 I-tositumomab with the BEAM regimen (BCNU, cytarabine, etoposide and melphalan). Twenty-three refractory and relapsed aggressive B-cell lymphoma patients received up to 7500 cGy total body dose of radiation. These investigators reported that short-and long-term toxicities were no different than those noted with BEAM and ASCT alone. At a median follow-up of 38 months, OS was 55% and event-free survival (EFS) was 39% in this group of poor prognosis NHL patients. Currently the BMT CTN, a cooperative group that focuses on stem cell transplantation, is pursuing a phase III study of rituximab/BEAM versus BEXXAR ( 131 I-tositumomab)/BEAM with ASCT for persistent and relapsed chemosensitive large B-cell lymphoma. Y-ibritumomab in combination with high-dose etoposide (40-60 mg/kg) and cyclophosphamide (100 mg/ kg). Thirty-one indolent and aggressive NHL patients were enrolled including 14 diffuse large B-cell and 12 mantle cell (MCL) NHL patients, 21% of whom were in first complete or partial remission at time of transplantation. Although one patient failed to engraft, there were no other engraftment delays: median time to absolute neutrophil count (ANC) greater than 500 ml and a platelet count of more than 20 000 mL were 10 and 12 days, respectively. At a median follow-up of 22 months, the 2-year estimated DFS was 78% and OS was 92%. Interestingly, although the total dose of radiation delivered was lower in this study than in that reported by Press et al. 27 noted above, the outcome is similar.
Recently, centers have attempted a weight-based dosing of the radioimmunoisotopes, which technically is easier to do. This allows appropriate radiation doses to be delivered to the target organs and to the tumor, but does not require extensive calculations that dosimetry-based dosing required. Fung et al. 31 at the City of Hope National Medical Center reported 12 poor-risk, aggressive NHL patients treated with 0.4 mCi/kg of 90 Y-ibritumomab and high-dose BEAM before ASCT. All patients engrafted, at a median time to reach an ANC greater than 1000 ml and platelets of more than 20 000 ml at 11 days. Eleven of 12 patients remain alive, disease-free at a median follow-up of 9 months. Finally, Winter et al. 32 recently presented a dose finding study using 90 Y-ibritumomab and BEAM with ASCT support in NHL. Forty-four patients received dosing that ranged from 0.3 to 1.2 mCi/kg to deliver 100-1700 cGy to the critical organs. Again, the toxicity profile was similar to those patients treated with BEAM alone. One patient developed mild hepatic veno-occlusive disease/sinusoidal obstruction syndrome at the 700 cGy dose. At the 1700 cGy dose level, one patient died of pneumonia and sepsis 10 days after ASCT and one patient died from septic emboli to the lung 13 days after ASCT. Three-year OS and DFS are 52 and 37%, respectively. These investigators recommended that the phase-II dose from this study be 0.8 mCi/ kg per recipient weight.
Front-line autotransplant in high-risk NHL patients
One area of controversy has been to determine if patients with NHL with a high-risk IPI may derive more benefit from an aggressive treatment approach. Rather than wait Table 4 Comparisons of autologous conditioning regimens using immunotherapy and radioimmunotherapy for a probable relapse of the disease (and an associated potential for increased resistance to therapy), high-dose chemotherapy could be used as a consolidation approach. Furthermore, this strategy would also reduce the number of regimens to which a patient is exposed and may limit exposure to drugs (such as etoposide) that potentially cause myelodysplasia or AML in the future. The final analysis of the GELA group LNH87-2 trial, which compared sequential chemotherapy versus high-dose therapy with cyclophosphamide, BCNU and etoposide and autologous transplant for newly diagnosed IPI high-risk patients, demonstrated improved DFS and OS for ASCT in a retrospective subset analysis of the data. 34 The effect did not extend to all patients and the study was hampered by a low number of patients not completing the assigned therapy. Other groups also have used dose intensification as part of an aggressive approach for high-risk NHL. The NHLCSG compared VACOP-B followed by either DHAP versus BEAM plus ASCT. They did not note an improvement in DFS or PFS. 35 Gianni et al. 13 compared high-dose sequential chemotherapy to MACOP-B in high-risk, newly diagnosed or relapsed NHL. The high-dose sequential chemotherapy group had a superior complete remission rate, DFS, EFS and freedom from relapse. OS showed a trend but not statistical significance for the high-dose cohort. The French GOELAMS group compared CHOP for eight cycles versus CEEP (cyclophosphamide, epirubicin, vindesine and prednisone) followed by BEAM and ASCT. EFS was higher in the patients receiving BEAM and ASCT (55 versus 37%, P ¼ 0.037) and OS was better in the high-intermediate IPI-risk group receiving BEAM and ASCT (74 versus 44%, P ¼ 0.001). 36 Currently, the US Intergroup is nearing completion of accrual on SWOG S9704, a trial designed to evaluate the OS and PFS of patients with intermediate-or high-grade NHL treated with CHOP (or CHOP-R for CD20 þ disease) versus CHOP ( þ R) followed by high-dose chemotherapy and ASCT. The study employs a cross-over design to allow salvage with ASCT once relapse has occurred, thus addressing early transplant or transplant at the time of relapse in high-risk patients.
Other NHL patient subsets
Future studies in this area may focus on a select subset of NHL patients, such as MCL, Burkitt's, lymphoblastic and T-cell NHL. MCL is an aggressive NHL that often is responsive to initial chemotherapy, but has a very high relapse rate. The MD Anderson Cancer Center treated newly diagnosed and relapsed MCL using four cycles of the HyperC-VAD/MA regimen and reported a 38% complete and 56% partial response rate. Patients then received consolidation therapy using either an ASCT or an allogeneic transplant. Forty-five patients were enrolled, 25 previously untreated. All patients who received a transplant achieved a complete remission. For the 25 previously untreated patients, 3-year OS and EFS rates were 92 and 72%, respectively, compared with 56 and 28% respectively, for a historic control group treated with a CHOP-like regimen. 37 These investigators also reported use of 6 to 8 cycles of HyperC-VAD/MA plus rituximab, without stem cell transplant, in previously untreated MCL patients. This prospective phase II trial of 97 patients, demonstrated a 97% response rate and 87% achieved either a CR or a CRu. At a median follow-up of 40 months, the 3-year FFS and OS rates were 64 and 82%, respectively, but without a plateau in the curves. For the subgroup of patients 65 years of age, the 3-year EFS rate was 73%. Five patients died from acute toxicity, four patients developed treatment-related MDS/ AML and three patients died while in remission for a total of eight (8%) treatment-related deaths. This approach was not recommended for patients over age 65 years due to the excess morbidity and mortality in that group. 38 Lack of superiority of one approach suggest that it will be necessary to complete a prospective, randomized study to define the role of upfront ASCT in MCL patients.
In aggressive, high-grade NHL, several effective regimens have been used, but 39, 40 20-45% of the adult patients will relapse. In the relapsed disease setting ASCT appears superior to conventional salvage chemotherapy. The EBMT reviewed 117 cases of adult Burkitt's and Burkitt's-like lymphoma and reported a 3-year 57% OS rate. Disease status at time of transplant had the biggest impact on survival with 72% surviving in first complete remission compared to only 37% in chemosensitive relapse and 7% in refractory disease. 41 Lymphoblastic lymphoma historically has been treated using an approach similar to that employed in acute lymphoblastic leukemia. The EBMT/UKLG evaluated 119 lymphoblastic lymphoma patients given standard induction therapy followed by randomization to continue conventional chemotherapy or proceed to ASCT. Sixty-five of the 98 eligible patients were randomized, 31 to ASCT and 34 to conventional chemotherapy. Neither EFS (55 versus 24%, P ¼ 0.065) nor OS were improved by ASCT and the study was terminated early due to low accrual. 42 The IBMTR/ABMTR reported observational database information and noted no differences in OS of patients treated using transplant. Bone marrow involvement and disease status beyond first remission, however, were associated with inferior outcomes. 43 T-cell NHL also has an inferior prognosis when compared to B-cell NHL after CHOP therapy. Blystad et al. 44 reported the use of various high-dose chemotherapy regimens and ASCT for chemosensitive relapsed or primary refractory T-cell NHL. OS at 36 months was 58% and anaplastic large cell lymphoma had a better prognosis than the other subtypes (79 versus 44%). 44 The GEL-TAMO group evaluated 35 patients who had an incomplete response to conventional chemotherapy (31 partial and 4 non-responders). Sixty-six percent attained a complete remission after an ASCT; at 5 years 37% were still alive and 55% of those in complete remission remained diseasefree. 45 In the relapsed setting the same group has noted an excellent response to ASCT. Post transplant 86% attained a CR with a 5-year OS of 56%. 46 Table 5 describes some of the future considerations for the use of ASCT in relapsed, aggressive NHL. The major issue is how to improve upon the anti-lymphoma effect of the regimens. While it may be some time before newer agents can proceed from developmental phase to incorporation into ASCT regimens, several studies suggest a role for the use of currently available agents such as topotecan, paclitaxel, gemcitabine and navelbine. 47, 48 Novel and more potent anti-lymphoma monoclonal antibodies are entering clinical trials and may have a role in the transplant setting. 49, 50 Another approach is to attack the tumor microenvironment with anti-angiogenesis inhibitors. High serum concentrations of vascular endothelial growth factor (VEGF) and basic fibroblastic growth factor have been associated with a negative outcome in NHL patients, particularly those with diffuse large B-cell lymphoma (DLBCL). 51 Ganjoo et al. 52 used bevacizumab, a VEGF-A inhibitor, combined with standard dose cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab (CHOP-R), as initial treatment for patients and with DLBCL. After 88 cycles given to the cohort, toxicity did not differ compared to historic controls using R-CHOP; no grade 3-4 proteinuria, heart failure or hemorrhage was observed. The response rate was 85% and included 38% complete responses, at a median follow-up of only 16.9 months, PFS at 1 year was 77%. 52 Further study of this combination will need to take place using a randomized clinical design.
Future considerations
The role of immunotherapy as part of mobilization, conditioning and post-ASCT remains an ongoing question. Promising results have been described in phase I and II trials but few, if any, phase III data yet are available although the BMT CTN immunoconjugate study described above is in progress.
Lenalidomide (Revlimid) is an immunomodulatory drug with activity in myeloma, myelodysplastic syndrome, chronic lymphocytic leukemia and MCL lymphoma. In lymphoma cell lines (U266 and LP-1) lenalidomide has an anti-proliferative effect while sparing the proliferative potential of normal B-cells or CD34-positive cells. 53 This agent may have a role in the treatment of NHL post-ASCT, especially to eradicate minimal residual disease. Owing to the myelosuppressive effects noted in treatment of myeloma and myelodysplastic syndrome, dosing studies must be designed carefully.
An important area to consider is reducing the toxicity of the mobilization and transplant strategies. Hake et al. 54 proposed that it is difficult to 'assign' blame, for example determine if hematopoietic stem cell damage occurred during initial chemotherapy and radiotherapy, salvage therapy, the mobilization procedure, the autologous transplant conditioning regimen, or occurred as a result of the rapid proliferation of cells in the post-transplant period. Priming chemotherapy for stem cell mobilization, especially the use of high-dose etoposide, appears to confer a 12-fold increased risk of secondary myelodysplasia and acute leukemia. 55 Mobilization regimens that do not include chemotherapy (especially etoposide) may reduce this risk. One alternative is the addition of AMD3100 to G-CSF that may facilitate harvesting of a higher number of CD34 þ cells for transplantation in lymphoma patients. 56 Individualized chemotherapy dosing may also improve the efficacy of ASCT. Intravenous busulfan allows easier dose adjustments and facilitates dose targeting in the transplant setting. IV busulfan treatment in combination provides a reliable mode of delivering the drug within the therapeutic window and potentially avoid toxic effects noted with other transplant regimens. 7, 40 The optimal AUC for busulfan in NHL, however, remains to be determined unlike the situation for agents such as carboplatin. Such 'targeting' of drugs within the therapeutic window potentially maximizes anti-tumor effect while minimizing organ toxicity.
Single nucleopeptide polymorphisms of certain genes may alter the biologic properties of the drugs we use in the conditioning regimens given before transplant. Variants of these genes (polymorphisms) can alter metabolism of drugs such as busulfan, 57 BCNU, 58 and cyclophosphamide 59 resulting in a higher rate of toxicity and death in some patients receiving these agents. If alerted to such a possibility, investigators could recognize the potential for greater injury due to chemotherapy and tailor treatment to the individual patient undergoing ASCT. Cytoprotectants such as amifostine or the endothelial growth stimulators (palifermin and velafermin) may also help reduce mucositis and gastrointestinal toxicity and decrease the potential for infections during transplant as well as alleviate or prevent patient discomfort. [60] [61] [62] Finally, new information on genetic disparity between patients may alter the approach we take in treating their disease. Differences in polymorphisms as noted above can affect drug efficacy and toxicity profile. Some tumors may not respond to rituximab due to differences in FC polymorphisms. 63 IL-2 has been used successfully to upregulate disease targets before rituximab therapy, enhance NK activity and restore potential anti-lymphoma effect. 64 Recently, changes in the standard approach for the treatment of NHL therapy has led to a new revised IPI, which has been suggested as a better predictor of outcome in patients treated with rituximab. 65 This R-IPI will need to be validated in transplant studies.
We have just begun our voyage on to the journey to 'curing' relapsed aggressive NHL. We remain optimistic that the approaches described above, including targeted or tailored therapy, may help improve treatment outcomes. Only time, patience and well-constructed clinical trials will tell if we are on the right road.
